Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Quotes, Forecast and News Summary

Q: What sector and industry does Madrigal Pharmaceuticals (MDGL) operate in?

Madrigal Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Madrigal Pharmaceuticals Stock (NASDAQ: MDGL) stock price, news, charts, stock research, profile.

Open	-
Close	-
Volume / Avg.	0 / 372.59K
Day Range	- - -
52 Wk Range	168.25 - 368.29
Market Cap	$6.92B
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	62
Short Interest	29.83%
Days to Cover	12.5

Recent News

Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?

Top mid-cap stock performers: MDGL (+51.70%), PRCT (+34.20%), GSAT (+33.98%), WGS (+31.17%), NXT (+25.91%), VFC (+25.82%), OMCL (+23.22%).

Lekha Gupta

Viking Rises 25% in a Month: Should You Buy or Wait?

Shares of Viking Therapeutics (NASDAQ: VKTX) have soared nearly 25% in the past month, all thanks to progress with its investigational obesity and non-alcoholic steatohepatitis (NASH) candidates, which management plans to advance to late-stage development by early 2025.

Zacks

What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?

Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment. Further trials needed to confirm efficacy and safety.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Jun

Jul

Aug

Oct

Nov

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.9

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	-
Close	-
Volume / Avg.	0 / 372.59K
Day Range	- - -
52 Wk Range	168.25 - 368.29
Market Cap	$6.92B
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	62
Short Interest	29.83%
Days to Cover	12.5

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Madrigal Pharmaceuticals (MDGL) stock?

You can purchase shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) through any online brokerage.

View our list of the best stock brokerages

Who are Madrigal Pharmaceuticals (MDGL) competitors?

Other companies in Madrigal Pharmaceuticals’s space includes: Legend Biotech (NASDAQ:LEGN), Avidity Biosciences (NASDAQ:RNA), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT) and Neurocrine Biosciences (NASDAQ:NBIX).

What is the forecast, or price target, for Madrigal Pharmaceuticals (MDGL) stock?

Madrigal Pharmaceuticals has a consensus price target of $347.00.

What is the current price for Madrigal Pharmaceuticals (MDGL)?

The stock price for Madrigal Pharmaceuticals (NASDAQ: MDGL) is $317.09 last updated November 20, 2024 at 5:26 PM EST.

Does Madrigal Pharmaceuticals (MDGL) pay a dividend?

There are no upcoming dividends for Madrigal Pharmaceuticals.

When is Madrigal Pharmaceuticals (NASDAQ:MDGL) reporting earnings?

Madrigal Pharmaceuticals’s Q3 earnings are confirmed for Thursday, October 31, 2024.

Is Madrigal Pharmaceuticals (MDGL) going to split?

There is no upcoming split for Madrigal Pharmaceuticals.

What sector and industry does Madrigal Pharmaceuticals (MDGL) operate in?

Madrigal Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Comments

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals (MDGL) Forecast